A case series on safety and tolerability of human umbilical cord-derived mesenchymal stem cells on patients in Malaysia

• Published in: SAGE open medical case reports Vol. 12; p. 2050313X241249622
• Main Authors: Yusof, Basmullah, Kamal, Iqmaliza, Lee, Ka Man, Chai, Siong Kiat, Zuo, Xia Lin, Ravichandran, Manickam, Ding, Ke Xiang, Fuloria, Neeraj Kumar, Tham, Seng Kong
• Format: Report
• Language: English
• Published: 01.01.2024
• ISSN: 2050-313X; 2050-313X
• DOI: 10.1177/2050313X241249622

Umbilical cord-derived mesenchymal stem cells for regenerative therapy are a promising treatment option for chronic illnesses. Umbilical cord-derived mesenchymal stem cells offer several advantages over other sources, which makes them an attractive option in tissue repair and regeneration. This clinical study describes a 1-year follow-up on the safety and tolerance of umbilical cord-derived mesenchymal stem cell therapy on nine patients in Malaysia. Patients were assessed for adverse effects, and liver function tests were carried out on both pre- and post-treatments. Umbilical cord-derived mesenchymal stem cells' effectiveness and safety were assessed by follow-up evaluations. All nine patients responded positively towards umbilical cord-derived mesenchymal stem cell therapy, without any adverse effects. After umbilical cord-derived mesenchymal stem cell therapy, a significant improvement was observed in liver functioning test outcomes, as haematological parameters and tumour markers were stable. The present study concludes that umbilical cord-derived mesenchymal stem cell therapy is well tolerated by Malaysian patients; however, further clinical screening must be done over a large number of patients population.